Old Web
English
Sign In
Acemap
>
authorDetail
>
Olanrewaju O. Okusanya
Olanrewaju O. Okusanya
Food and Drug Administration
Medicine
Internal medicine
Population
Oncology drugs
Oncology
5
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies
2020
Clinical Pharmacology & Therapeutics
Obinna N. Obianom
Olanrewaju O. Okusanya
Justin C. Earp
Theingi M. Thway
Show All
Source
Cite
Save
Citations (1)
Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies
2019
The Lancet Child & Adolescent Health
Steven T. Bird
Richard S. Swain
Fang Tian
Olanrewaju O. Okusanya
Peter Waldron
Mona Khurana
Elizabeth L Durmowicz
Yong Ma
Jacqueline M. Major
Kate Gelperin
Show All
Source
Cite
Save
Citations (8)
Dose Selection of Targeted Oncology Drugs in Early Development: Time for Change?
2018
Bahru A. Habtemariam
Lian Ma
Brian Booth
Olanrewaju O. Okusanya
Nitin Mehrotra
Show All
Source
Cite
Save
Citations (0)
Dose Selection of Targeted Oncology Drugs in Early Development
2018
Bahru A. Habtemariam
Lian Ma
Brian Booth
Olanrewaju O. Okusanya
Nitin Mehrotra
Show All
Source
Cite
Save
Citations (0)
Intramuscular (IM) or intravenous (IV): Impact of Erwinia asparaginase route of administration on asparaginase activity.
2015
Journal of Clinical Oncology
Olanrewaju O. Okusanya
Patricia Dinndorf
Julie Bullock
Bahru A. Habtemariam
Nitin Mehrotra
Albert B. Deisseroth
Gregory H. Reaman
Nam Atiqur Rahman
Ann T. Farrell
Show All
Source
Cite
Save
Citations (1)
1